Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-09-18, Stock:ABBV, The news for the past five days is as follows:
2018-09-11: NEWS1: Minimal Residual Disease Negativity Data, a Measure of Undetectable Disease, Added to VENCLEXTA® (venetoclax tablets) Label.
2018-09-12: NEWS1: 5 Growth Stocks to Buy for Reliable Income in Retirement.NEWS2: 5 Growth Stocks to Buy for Reliable Income in Retirement.NEWS3: 5 Growth Stocks to Buy for Reliable Income in Retirement.NEWS4: The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FIZZ, RMTI, TTPH, ABBV and GDS.NEWS5: AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia.NEWS6: AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia.NEWS7: SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline – September 24, 2018.NEWS8: AbbVie Gets FDA Nod for Venclexta Label Expansion in Leukemia.
2018-09-13: NEWS1: AbbVie Rises 3.02%.NEWS2: Should Value Investors Consider AbbVie (ABBV) Stock Now?.NEWS3: Should Value Investors Consider AbbVie (ABBV) Stock Now?.NEWS4: AbbVie Inc. -- Moody's assigns Baa2 to AbbVie's sr. notes; stable outlook.NEWS5: Should Value Investors Consider AbbVie (ABBV) Stock Now?.NEWS6: AbbVie Presents Upadacitinib Longer-Term (32-Week) and Patient-Reported Outcomes Data from Phase 2b Atopic Dermatitis Study at 27th European Academy of Dermatology and Venereology (EADV) Congress.NEWS7: AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis.
2018-09-14: NEWS1: Noteworthy ETF Outflows: MTUM, ABBV, ISRG, SPGI.NEWS2: Noteworthy ETF Outflows: MTUM, ABBV, ISRG, SPGI.NEWS3: Roche's Child Arthritis Drug's New Formulation Gets FDA Nod.NEWS4: Roche's Child Arthritis Drug's New Formulation Gets FDA Nod.NEWS5: Pharma/Biotech Stocks to Watch This Prostate Cancer Month.NEWS6: Pharma/Biotech Stocks to Watch This Prostate Cancer Month.NEWS7: Top Stock Reports for JPMorgan, Mastercard & AbbVie.NEWS8: 3 Things You Might Be Overlooking With AbbVie.NEWS9: 3 Things You Might Be Overlooking With AbbVie.NEWS10: Pharma/Biotech Stocks to Watch This Prostate Cancer Month.NEWS11: Roche&apos;s Child Arthritis Drug&apos;s New Formulation Gets FDA Nod.NEWS12: 3 Things You Might Be Overlooking With AbbVie.NEWS13: Neurocrine Biosciences: Analysts Are Mostly Positive.NEWS14: Today’s Research Reports on Stocks to Watch: AbbVie and Progenics Pharmaceuticals.NEWS15: A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis.NEWS16: A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis.NEWS17: Johnson & Johnson Expands Blood Cancer Portfolio with Approval.NEWS18: A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis.
2018-09-17: NEWS1: Why Gilead Stock Is a Sleepy Giant Waiting to Break Out.NEWS2: Why Gilead Stock Is a Sleepy Giant Waiting to Break Out.NEWS3: Why Gilead Stock Is a Sleepy Giant Waiting to Break Out.NEWS4: The Zacks Analyst Blog Highlights: JPMorgan, Mastercard, AbbVie, CVS Health and Estee Lauder.NEWS5: The Zacks Analyst Blog Highlights: JPMorgan, Mastercard, AbbVie, CVS Health and Estee Lauder.NEWS6: DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline - September 24, 2018.NEWS7: The Zacks Analyst Blog Highlights: JPMorgan, Mastercard, AbbVie, CVS Health and Estee Lauder.NEWS8: AbbVie to Host Third-Quarter 2018 Earnings Conference Call.

Answer: Decrease